Richardson A, Demoliou-Mason C, Barnard E A
Medical Research Council Molecular Neurobiology Unit, Medical Research Council Centre, Cambridge, United Kingdom.
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10198-202. doi: 10.1073/pnas.89.21.10198.
Opioid receptors are currently classified as mu, delta, and kappa types, but various subtypes have also been proposed. We have investigated whether subtypes exist by using [3H]bremazocine. [3H]Bremazocine binds to twice as many naloxone-sensitive sites as other nonselective opioid agonists, as shown in four membrane types that have very different ratios of mu, delta, and kappa receptor types. [3H]Bremazocine binding is completely inhibited by an excess (in unlabeled form) of other opioid ligands, with Hill coefficients of 0.8-0.95. These paradoxes can be explained if there are high- and low-affinity states of the mu, delta, and kappa receptors and bremazocine binds with similar affinities to both states. We propose that these states are the guanine nucleotide-binding protein (G-protein)-coupled form and the uncoupled form of each receptor. As evidence for this proposal, the [3H]bremazocine binding suffered little or no loss with G-protein-uncoupling treatments, whereas binding of other opioid agonists was fully sensitive. We conclude that [3H]bremazocine offers a tool for the measurement of the total pools of coupled and uncoupled opioid receptors and that much of the previous characterization of opioid receptor subtypes reflects, instead, a significant pool of G-protein-uncoupled opioid receptors.
阿片受体目前被分为μ、δ和κ三种类型,但也有人提出了各种亚型。我们使用[³H]布瑞马唑辛研究了是否存在亚型。如在四种具有非常不同的μ、δ和κ受体类型比例的膜类型中所示,[³H]布瑞马唑辛与纳洛酮敏感位点的结合数量是其他非选择性阿片类激动剂的两倍。[³H]布瑞马唑辛的结合被过量(未标记形式)的其他阿片类配体完全抑制,希尔系数为0.8 - 0.95。如果μ、δ和κ受体存在高亲和力和低亲和力状态,且布瑞马唑辛与这两种状态的亲和力相似,那么这些矛盾现象就可以得到解释。我们提出这些状态是每种受体的鸟嘌呤核苷酸结合蛋白(G蛋白)偶联形式和解偶联形式。作为这一观点的证据,[³H]布瑞马唑辛的结合在G蛋白解偶联处理后几乎没有损失,而其他阿片类激动剂的结合则完全敏感。我们得出结论,[³H]布瑞马唑辛为测量偶联和解偶联阿片受体的总库提供了一种工具,而且之前对阿片受体亚型的许多表征反而反映了大量G蛋白解偶联的阿片受体。